The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06616727
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus
Phase 1
Not yet recruiting
- Conditions
- Lupus Erythematosis
- Interventions
- Biological: After preconditioning with chemotherapy, F01 will be evaluated.
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06468683
- Locations
- 🇨🇳
Shanghai jiaotong University School of Medicine,Renji Hospital, 上海市, 上海市, China
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Phase 1
Recruiting
- Conditions
- Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma
- Interventions
- Drug: SNC115 injection
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT06384482
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Phase 1
Recruiting
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Drug: After preconditioning with chemotherapy, F01 will be evaluated.
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT06206902
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
Phase 1
Recruiting
- Conditions
- Recurrent Glioblastoma Multiforme
- Interventions
- Drug: SNC-109 CAR-T Cells
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05868083
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
Phase 1
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Biological: CAR-NK-CD19 Cells
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 2
- Registration Number
- NCT05563545
- Locations
- 🇨🇳
Hebei Yanda Ludaopei Hospital, Sanhe, Hebei, China
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05346198
- Locations
- 🇨🇳
Hematology Department of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
🇨🇳Hematology Department of the First Affiliated Hospital of Zhejiang University, Hangzhou, China
© Copyright 2025. All Rights Reserved by MedPath